Local Therapy for Limited Acquired Resistance
Video
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.
Elderly Patients: Selecting Appropriate Systemic Treatment Agents
Video
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.
ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib
Video
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC
Video
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Targeted Therapies in a Post-Operative/Adjuvant Setting
Video
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1
Video
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
Article
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Here Today Thanks to Research
Article
ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?
Join GRACE at the 2015 ALK, ROS1 & EGFR Lung Cancer Patient Forum
Article
WHAT: Acquired Resistance in Lung Cancer Patient Forum
WHEN: Saturday, Oct. 3, 2015
WHERE: Marriott Waterfront San Francisco, 1800 Old Bayshore Hwy, Burlingame, CA 94010
WHO: ALK, ROS1 & EGFR lung cancer patients and their caregivers
REGISTER HERE
Breakthroughs in Lung Cancer from 2014 from Thomas John, MD
Article
Dr. Thomas John of the Olivia Newton-John Cancer Center in Melbourne, Australia presents his favorite breakthroughs in lung cancer from 2014.
For those who wish to access the PDF, it's here: Thomas John, MD Top Four Lung Cancer Highlights 2014
Agree? Disagree? What are you looking forward to in 2015?